Utama › Karsinoma Urotelial (Sel Transisi) › Illinois › Chicago
Kajian klinikal Karsinoma Urotelial (Sel Transisi) di Chicago, IL
14 kajian untuk Karsinoma Urotelial (Sel Transisi) sedang mencari peserta di lokasi dalam dan sekitar Chicago (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Mengambil pesertaFasa 1
- Exelixis Clinical Site #26, Chicago
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
Mengambil pesertaFasa 3
- University of Illinois, Chicago
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Mengambil pesertaFasa 2
- Rush MD Anderson Cancer Center, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
Mengambil pesertaKajian pemerhatian
- Northwestern University, Chicago
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
Mengambil pesertaFasa 1/2
- University of Chicago Medical Center ( Site 1037), Chicago
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Mengambil pesertaFasa 3
- University of Illinois at Chicago, Chicago
- University of Chicago Medical Center, Chicago
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Mengambil pesertaFasa 1
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Mengambil pesertaFasa 2
- UChicago Medicine - River East, Chicago
- University of Chicago Medical Center, Chicago
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Mengambil pesertaFasa 1/2
- The University of Chicago Medical Center - Oncology, Chicago
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
Mengambil pesertaFasa 2
- Site 02-012 - University of Chicago, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Mengambil pesertaKajian pemerhatian
- Massive Bio SYNERGY-AI site, Chicago
Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer
Mengambil pesertaKajian pemerhatian
- Jesse Brown Department Of Veterans Affairs Medical Center, Chicago
A Study of NX-1607 in Adults With Advanced Malignancies
Mengambil pesertaFasa 1
- University of Chicago, Chicago
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
Mengambil pesertaFasa 2
- Northwestern University, Chicago
Kajian Karsinoma Urotelial (Sel Transisi) di bandar lain
- Nashville, TN23 kajian
- New York City, NY22 kajian
- Dallas, TX18 kajian
- Edison, NJ18 kajian
- Houston, TX18 kajian
- Los Angeles, CA17 kajian
- Queens, NY15 kajian
- Arlington, VA12 kajian
- San Antonio, TX11 kajian
- Boston, MA11 kajian
- Austin, TX10 kajian
- Orange, CA10 kajian
Kajian lain di Chicago
- Kanser Paru-paru Bukan Sel Kecil61 kajian
- Kanser Payudara58 kajian
- Kanser (semua jenis)51 kajian
- Kanser Metastatik45 kajian
- Kanser Prostat45 kajian
- Obesiti41 kajian
- Kanser Paru-paru41 kajian
- Kanser Ovari36 kajian
- Strok34 kajian
- Kanser Kolorektal33 kajian
- Kegagalan Jantung31 kajian
- Berat Badan Berlebihan28 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.